Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin

Jeong, Hyehyun and Jeong, Jae Ho and Kim, Kyu-Pyo and Lee, Sang Soo and Oh, Dong Wook and Park, Do Hyun and Song, Tae Jun and Park, Yangsoon and Hong, Seung-Mo and Ryoo, Baek-Yeol and Yoo, Changhoon (2021) Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin. Cancers, 13 (2). p. 161. ISSN 2072-6694

[thumbnail of cancers-13-00161.pdf] Text
cancers-13-00161.pdf - Published Version

Download (911kB)

Abstract

The prognosis of advanced biliary tract cancer (BTC) is poor with the standard gemcitabine and cisplatin (GemCis) regimen. Given that the rates of human epidermal growth factor receptor 2 (HER2) positivity in BTC reaches around 15%, HER2-targeted therapy needs further investigation. This study aims to evaluate the preliminary efficacy/safety of first-line trastuzumab-pkrb plus GemCis in patients with advanced BTC. Patients with unresectable/metastatic HER2-positive BTC received trastuzumab-pkrb (on day 1 of each cycle, 8 mg/kg for the first cycle and 6 mg/kg for subsequent cycles), gemcitabine (1000 mg/m2 on day 1 and 8) and cisplatin (25 mg/m2 on day 1 and 8) every 3 weeks. Of the 41 patients screened, 7 had HER2-positive tumours and 4 were enrolled. The median age was 72.5 years (one male). Primary tumour locations included extrahepatic (N = 2) and intrahepatic (N = 1) bile ducts, and gallbladder (N = 1). Best overall response was a partial response in two patients and stable disease in two patients. Median progression-free survival (PFS) was 6.1 months and median overall survival (OS) was not reached. The most common grade 3 adverse event was neutropenia (75%), but febrile neutropenia did not occur. No patient discontinued treatment due to adverse events. Trastuzumab-pkrb with GemCis showed promising preliminary feasibility in patients with HER2-positive advanced BTC.

Item Type: Article
Subjects: STM Open Library > Medical Science
Depositing User: Unnamed user with email support@stmopenlibrary.com
Date Deposited: 25 Jan 2023 09:19
Last Modified: 02 May 2024 05:39
URI: http://ebooks.netkumar1.in/id/eprint/60

Actions (login required)

View Item
View Item